- €13.07bn
- €12.06bn
- €3.93bn
Brief: Ipsen's Iqirvo Demonstrates Statistically Significant Improvement In ALP Normalisation In Patients With PCB
Brief: Ipsen Announces Positive Dysport Phase III Results For Migraine Prevention
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
French biotech Ipsen to buy Memo Therapeutics for $230 million upfront
Brief: Ipsen To Acquire Memo Therapeutics AG, Adding First-In-Class BK Polyomavirus Antibody
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
French biotech company Ipsen to buy Kartos Therapeutics for $450 million
Brief: Ipsen To Buy Kartos Therapeutics In Definitive Merger Agreement
Brief: Euronext Includes Maurel et Prom, Mersen In SBF 120, Excludes Elior Group, Nexity
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients
Brief: Ipsen Initiates A New Share Buy-Back Program
Brief: FDA Alerts Health Care Providers, Patients On Increased Risk Of New Blood Cancers With Tazverik Use
France's Ipsen Q1 revenue rises 17%, rare disease sales more than double